Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Sevelamer Carbonate for Reducing Endotoxemia and Immune Activation: A Proof of Concept Study

NCT01543958 is registered in ClinicalTrials.gov with Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections as lead sponsor.

NCT NCT01543958
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01543958 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Sevelamer Carbonate for Reducing Endotoxemia and Immune Activation: A Proof of Concept Study
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2011
Completion date
November 30, 2012
Enrollment
40 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

hiv-1 infection